drugset / Trial / NCT02287259

Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study)

NCT02287259

Phase 4 Completed 50 enrolled Tadashi Hasegawa
RandomizedParallel-groupOpen-labelTreatment

Summary

Determine the efficacy and tolerability of olanzapine for treatment of acute depression in patients with bipolar II or bipolar disorder NOS compared with lithium.

Timeline

Start
2014-11
Primary completion
2019-03-31
Completion
2019-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lithium Unknown 400 mg Oral
Subject Olanzapine Small molecule 2.5 mg Oral

Indications